Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Dr. Miers said Bryan Health is the only hospital in Lincoln that offers Spravato and the only hospital that offers ElectroConvulsive therapy, also known as ‘electric shock therapy’. To learn ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...